Recipharm/Consort
Transaction details
The proposed acquisition whereby Recipharm Holdings Limited will acquire sole control of Consort Medical Plc has been cleared by the Competition and Consumer Protection Commission.
Case details
- Notification date:20 December 2019
- Publication date:20 December 2019
- Economic sector:Manufacturing - C
- Economic sub-sector:Manufacture of pharmaceuticals - C.21
- Outcome:Cleared
Documents
M.19.046 Merger AnnouncementPDF | 429 KBM.19.046 Merger Announcement PDF | 429 KB - Opens in new window
M.19.046 DeterminationPDF | 642 KBM.19.046 Determination PDF | 642 KB - Opens in new window
Timetable
Parties Involved
Recipharm Holdings Limited
Recipharm Holdings Limited is a wholly owned subsidiary of the Recipharm Group.
Recipharm Group is a global contract development and manufacturing organisation (CDMO). It is a global provider of drug development and manufacturing services to the pharmaceutical industry.
Recipharm Group offers manufacturing services for finished dose pharmaceuticals (FDPs) and active pharmaceutical ingredients (APIs).
Recipharm Group has no manufacturing or development facilities in the State. However, it does have sales to pharmaceutical companies based in the State.
Consort Medical Plc
Consort is a global CDMO providing drug formulation and manufacture (both FDPs and APIs) as well as drug delivery device development and manufacture to pharmaceutical partners globally and in the State.
Contacts
Barry O'Donnell barryodonnell@ccpc.ie
Craig Whelan craigwhelan@ccpc.ie
